Plasmodium falciparum malaria and atovaquone-proguanil treatment failure

Emerging Infectious Diseases

Volumn 14, Issue 2, 2008, Pages 320-322

  Durand, Rémy ^a,b,c   Prendki, Virginie ^a   Cailhol, Johann ^a   Hubert, Véronique ^c   Ralaimazava, Pascal ^a   Massias, Laurent ^c   Bouchaud, Olivier ^a   Le Bras, Jacques ^a,c,d  

^a AVICENNE HOSPITAL   (France)

^b PÔLE UNIVERSITAIRE LÉONARD DE VINCI   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; CYCLOGUANIL; MEROZOITE SURFACE PROTEIN 2; PARACETAMOL; QUININE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD SMEAR; CASE REPORT; CHILL; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IC 50; MALARIA; MALE; PARASITEMIA; PLASMODIUM FALCIPARUM; RETREATMENT; TRAVEL; TROPHOZOITE;

EID: 38949160790     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1402.070945     Document Type: Article

References (15)

1. Griffith KS, Lewis LS, Mali S, Parise ME. Treatment of malaria in the United States: a systematic review. JAMA. 2007;297:2264-77.
2. Musset L, Bouchaud O, Matheron S, Massias L, Le Bras J. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect. 2006;8:2599-604.
3. Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, Pasvol G. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar J. 2002;1:1.
4. David KP, Alifrangis M, Salanti A, Verstergaard LS, Ronn A, Bygbjerg IB. Atovaquone/proguanil resistance in Africa: a case report. Scand J Infect Dis. 2003;35:897-8.
5. Schwartz E, Bujanover S, Kain KC. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis. 2003;37:450-1.
6. Färnert A, Lindberg J, Gil P, Swedberg G, Berqvist Y, Thapar MM, et al. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ. 2003;326:628-9.
7. Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Mühlen M, et al. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J Infect Dis. 2004;190:1541-6.
8. Kuhn S, John Gill M, Kain KC. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune North American traveller to West Africa. Am J Trop Med Hyg. 2005;72:407-9.
9. Legrand E, Demar M, Volney B, Ekala MT, Quinternet M, Bouchier C, et al. First case of emergence of atovaquone resistance in Plasmodium falciparum during second-line atovaquone-proguanil treatment in South America. Antimicrob Agents Chemother. 2007;51:2280-1.
10. Musset L, Le Bras J, Clain J. Parallel evolution of adaptative mutations in Plasmodium falciparum mitochondrial DNA during atovaquone-proguanil treatment. Mol Biol Evol. 2007;24:1582-5.
11. Musset L, Pradines B, Parzy D, Durand R, Bigot P, Le Bras J. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother. 2006;57:110-5.
12. Jafari S, Le Bras J, Bouchaud O, Durand R. Plasmodium falciparum clonal population dynamics during malaria treatment. J Infect Dis. 2004;189:195-203.
13. Hussein Z, Eaves J, Hutchinson DB, Canfield CJ. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin Pharmacol Ther. 1997;61:518-30.
14. Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother. 1999;43:1334-9.
15. Wichmann O, Muehlen M, Gruss H, Mockenhaupt FP, Suttorp N, Jelinek T. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Malar J. 2004;3:14.